Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:
“Small preview from Wednesday’s SABCS24 session on the future of ADCs
Question: what do all these ongoing phase 3 ADC trials have in common?
Dec 11, 3.30 pm, Hemisfair Ballroom 1-2.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.